{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:17:28Z","timestamp":1769573848906,"version":"3.49.0"},"reference-count":30,"publisher":"Korean Association of Internal Medicine","issue":"5","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA22C0012"],"award-info":[{"award-number":["HA22C0012"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:p>Background\/Aims: Little attention is paid to chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL\/SLL.Methods: A total of 141 patients diagnosed with CLL\/SLL between January 2010 and March 2020 who received systemic therapy were analyzed in this multicenter retrospective study.Results: The median patient age was 66 years at diagnosis, and 68.1% were male. The median interval from diagnosis to initial treatment was 0.9 months (range: 0\u201377.6 months), and the most common treatment indication was progressive marrow failure (50.4%). Regarding first-line therapy, 46.8% received fludarabine, cyclophosphamide, plus rituximab (FCR), followed by chlorambucil (19.9%), and obinutuzumab plus chlorambucil (GC) (12.1%). The median progression-free survival (PFS) was 49.3 months (95% confidence interval [CI], 32.7\u201361.4), and median overall survival was not reached (95% CI, 98.4 mo\u2013 not reached). Multivariable analysis revealed younger age (\u2264 65 yr) (hazard ratio [HR], 0.46; &lt;i&gt;p&lt;\/i&gt; &lt; 0.001) and first-line therapy with FCR (HR, 0.64; &lt;i&gt;p&lt;\/i&gt; = 0.019) were independently associated with improved PFS. &lt;i&gt;TP53&lt;\/i&gt; aberrations were observed in 7.0% (4\/57) of evaluable patients. Following reimbursement, GC became the most common therapy among patients over 65 years and second in the overall population after 2017.Conclusions: Age and reimbursement mainly influenced treatment strategies. Greater effort to apply risk stratifications into practice and clinical trials for novel agents could help improve treatment outcomes in Korean patients.<\/jats:p>","DOI":"10.3904\/kjim.2022.408","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T04:07:57Z","timestamp":1687752477000},"page":"747-757","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment pattern of chronic lymphocytic leukemia\/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)"],"prefix":"10.3904","volume":"38","author":[{"given":"Jung Sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myoung Joo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Ae","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunkyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Joon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-220X","authenticated-orcid":true,"given":"Jung Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2270","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100930"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30029-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003453"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01629-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01580"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0715-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200012283432602"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2389533\/v1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1286-z"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2019.210"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5045\/br.2021.2021102"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"ref16","volume-title":""},{"key":"ref17","first-page":"928","volume-title":"; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an","author":"Eichhorst","year":"2016"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07226.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14258"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200204"},{"key":"ref21","first-page":"1146","volume-title":"Richter\u2019s transformation in chronic lymphocytic leukemia","author":"Jain","year":"2012"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000716"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v100.4.1177.h81602001177_1177_1184"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30212-1"},{"key":"ref25","volume-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma [Internet]"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004824"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060408"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.322"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.444"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/kjim.org\/upload\/kjim-2022-408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.408","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/upload\/kjim-2022-408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T07:56:33Z","timestamp":1694073393000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2022.408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2022.408","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"2022-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}